Express Mail Label No. EV 326 984 937 US

12-18-06

FM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INATE APPLICATION OF: GRYAZNOV ET AL.

PPLICATION OF GRYAZNOV ET AL.

FILED: May 3, 2006

APPLICATION No.: 10/578,530

FOR: RNA AMIDATES AND THIOAMIDATES FOR

RNAI

EXAMINER: TO BE ASSIGNED

Attorney Docket No.: 38797-8016.US00

ART UNIT: 1600

CONF. NO: 5144

<u>Information Disclosure Statement Within Three Months of</u> <u>Application Filing or Before First Action – 37 C.F.R. § 1.97(b)</u>

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

DEC 1 4 2006

A. Timing of Submission

This information disclosure is being filed within three months of the filing date of this application or date of entry into the National Stage of an International Application or before the mailing date of a first Office Action on the merits or before the mailing date of a first Office Action on the merits after the filing of a Request for Continued Examination under 37 CFR §1.114, whichever occurs last (37 CFR 1.97(b)(4)). The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

B. Cited Information

- Copies of references 1-5 are issued patent(s) and published application(s) and are not included (see C.F.R. § 1.98(a)(2)(ii)).

C. Effect of Information Disclosure Statement (37 C.F.R. § 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or

Attorney Docket No.: 38797-8016.US00

is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

D. Fee Payment

الم برهم

No fees are believed due because this Information Disclosure Statement is being filed before the mailing date of the first Office Action. However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2207.

E. Patent Term Adjustment (37 C.F.R. § 1.704(d))

The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).

Respectfully submitted, Perkins Coie LLP

Date: 12-14-2006

LeeAnn Gorthey

Registration No.37,337

Correspondence Address:

Customer No. 22918
Perkins Coie LLP
P.O. Box 2168
Menlo Park, California 94026
(650) 838-4300

په قسر شهو		STATEMENT I Form PTO-1	N DISCLOSURE BY APPLICANT 449 (Modified) eets if necessal	DEC 1 4 2006 8
				PARMAR
She	eet	1	of .	1

COMPLETE IF KNOWN				
Application Number	10/578,530			
Confirmation Number	5144			
Filing Date	May 3, 2006			
First Named Inventor	Gryaznov et al.			
Group Art Unit	1600			
Examiner Name	To be Assigned			
Attorney Docket No.	38797-8016.US00			

-						U.S. PATENT DOCUMENTS				
Examiner				Code	Name of Patentee or Inventor		Date of Publication or Filing Dat of Cited	Pages, Columns, Lin Where Relevant Passages or Releva		
Initials* No. NUMBER (if known) 1. 2004/0053875		 	of Cited Document Kruetzer, Roland et al.		3/18/0					
· ·-	2.				Zernicka-Goetz, Magdalena et al.		2/6/03			
	3. 2002/0162126			Beach, David et al.		10/31/0				
.,,,	4.						8/22/0			
		2002/0114784			Li, Yin-Xiong et al.				-	
	5.	200	2/00863	56		Tuschl, Thomas <i>et al</i> .		7/4/02		
	ı — :				FO	REIGN PATENT DOCUMENTS	·		•	
Examiner Initials*	Cite No.	Fore	eign Patent o	K	ation ation Code	· · · _	Pub Fil	Date of olication or ling Date of Cited ocument	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
								·		
			ОТНІ	R PR	IOR AF	RT-NON PATENT LITERATURE D	OCU	MENTS		
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.								
	6.	International Search Report from PCT/US04/032780 Published as WO05/047506 A1								
	7.	Bertrand et al., "The Expression Cassette Determines the Functional Activity of Ribozymes in Mammalian Cells by Controlling Their Intracellular Localization", RNA, 3:75-88 (1997).								
	8.	Elbashir et al., "Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate", Embo Journal, 20(23):6877-6888 (2001).								
	9.	Good et al., "Expression of Small, Therapeutcis RNAs in Human Cell Nuclei", Gene Therapy, 4:45-54 (1997).								
		Gryaznov S M: "Oligonucleotide N3'->P5' phosphoramidates as potential therapeutic								
	10.	agents" Biochimica et Biophysica ACTA, 1489(1):131-140 (1999). Matray et al., Nucleic Acids Research, 27(20):3976-3985 (1999). McCaffrey et al., "RNA Interference in Adult Mice", Nature, 418:38-39 (2002).								
	11.									
	12.									
	13.	Wianny et al., "Specific Interference with gene Function by Double-Stranded RNA in Early Mouse Development", Nature Cell Biology, 2:70-75 (1999).								

EXAMINER		DATE CONSIDERED			
*EXAMINER:	Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not				
	considered. Include copy of this form with next communication to application(s).				